SRRK

Scholar Rock Holding Corp. 10-Q Summary: Q1 2025

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Scholar Rock is a late-stage biopharmaceutical company focused on neuromuscular diseases, cardiometabolic disorders, and oncology. The company has no commercial product revenue and relies on equity financings and debt facilities to fund operations. Key milestones include the submission of a Biologics License Application (BLA) for apitegromab (SMA treatment) to the FDA in January 2025 (PDUFA date: September 22, 2025) and a Marketing Authorisation Application (MAA) to the EMA in March 2025.

Key Financial Metrics

Note: The company reported no revenue for the period. Cash burn was significant, with cash and marketable securities decreasing by approximately $72.9 million from the prior quarter.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by 31.4% year-over-year, driven by higher operating expenses.
• Expense Growth:
  • R&D Expenses: Increased 13.0% to $48.7 million, primarily due to higher costs for the cardiometabolic program (SRK-439) and drug supply manufacturing for apitegromab.
  • G&A Expenses: Increased 85.4% to $28.4 million, driven by increased headcount, equity-based compensation (including award modifications), and professional service fees.
• Debt Restructuring: In February 2025, the company entered into an Amended and Restated Loan and Security Agreement with Oxford Finance, consolidating existing tranches and extending the interest-only period through March 2029. Total borrowing capacity is up to $200 million, with $50 million currently outstanding.
• Management Transition: Effective April 27, 2025 (subsequent to period end), David Hallal was appointed CEO, replacing Jay T. Backstrom who transitioned to Senior Advisor.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($364.4 million) are sufficient to fund operations into 2027. However, additional capital will be required to complete clinical development and commercialization.
• Commercialization Timeline: If approved, apitegromab is expected to launch commercially in the U.S. in Q4 2025 and in Europe in 2026.
• Clinical Pipeline Updates:
  • Apitegromab (SMA): Positive Phase 3 SAPPHIRE results announced; BLA under priority review.
  • Cardiometabolic: Phase 2 EMBRAZE trial (apitegromab in obesity) enrollment completed; top-line results expected Q2 2025. SRK-439 IND submission targeted for Q3 2025.
  • Oncology: Phase 1 DRAGON trial (SRK-181) enrollment completed; data presented showing responses in anti-PD-(L)1 resistant patients.
• Risks: Key risks include the uncertainty of regulatory approval for apitegromab, the need for additional financing, reliance on third-party manufacturers, and the potential for clinical trial delays or failures in the pipeline.

Investor Verification Checklist

• Regulatory Status: Verify the FDA's PDUFA action date (September 22, 2025) and any potential delays in the review of the apitegromab BLA.
• Cash Runway: Confirm the company's burn rate and the sufficiency of the $364.4 million cash balance to reach commercialization without dilutive financing.
• Debt Covenants: Review the terms of the Amended and Restated Loan and Security Agreement for covenants that could restrict operations or trigger default.
• Clinical Data: Monitor the release of top-line results from the EMBRAZE trial (expected Q2 2025) and any new data from the DRAGON trial.
• Management Stability: Assess the impact of the recent CEO transition on strategic execution and commercial preparation.